RPTX - Repare Therapeutics Inc.
IEX Last Trade
1.265
-0.010 -0.791%
Share volume: 4,138
Last Updated: Fri 27 Dec 2024 08:29:44 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.28
-0.01
-0.78%
View ratios
Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
Report Date | 2022-08-04 | 2022-11-09 | 2023-02-28 | 2023-05-09 | 2023-08-09 | 2023-11-09 | 2024-02-28 | 2024-05-07 | |
Assets | |||||||||
Total Assets | 308.044 M | 409.158 M | 364.075 M | 336.306 M | 301.588 M | 286.407 M | 253.901 M | 263.084 M | |
Current Assets | 289.738 M | 390.597 M | 353.979 M | 325.526 M | 291.925 M | 275.093 M | 243.688 M | 254.670 M | |
Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Other Current Assets | 3.242 M | 5.635 M | 5.715 M | 4.389 M | 4.201 M | 5.551 M | 4.749 M | 3.463 M | |
Short Term Investments | 3.242 M | 5.635 M | 5.715 M | 4.389 M | 4.201 M | 5.551 M | 4.749 M | 3.463 M | |
Total Receivables | 4.407 M | 14.609 M | 4.323 M | 7.013 M | 7.032 M | 19.470 M | 15.312 M | 14.206 M | |
Current Cash | 282.089 M | 370.353 M | 343.941 M | 314.124 M | 280.692 M | 250.072 M | 223.627 M | 237.001 M | |
Total Non-current Assets | 18.306 M | 18.561 M | 10.096 M | 10.780 M | 9.663 M | 11.314 M | 10.213 M | 8.414 M | |
Property Plant Equipment | 5.124 M | 4.683 M | 4.228 M | 5.396 M | 4.821 M | 4.722 M | 4.215 M | 3.714 M | |
Other Assets | 6.953 M | 6.401 M | 5.868 M | 5.384 M | 4.842 M | 6.592 M | 5.998 M | 4.700 M | |
Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Liabilities and shareholders’ equity | |||||||||
Total Liabilities and shareholders’ equity | 308.044 M | 409.158 M | 364.075 M | 336.306 M | 301.588 M | 286.407 M | 253.901 M | 263.084 M | |
Total liabilities | 82.527 M | 103.382 M | 84.558 M | 85.062 M | 56.174 M | 53.039 M | 41.819 M | 31.131 M | |
Total current liabilities | 39.440 M | 61.871 M | 78.619 M | 80.935 M | 53.253 M | 48.972 M | 39.079 M | 30.570 M | |
Accounts Payable | 4.991 M | 9.345 M | 461.000 K | 3.620 M | 4.893 M | 5.438 M | 2.400 M | 6.825 M | |
Other liabilities | 38.592 M | 37.744 M | 2.682 M | 1.347 M | 695.000 K | 2.476 M | 1.730 M | 0.000 | |
Current long term debt | 2.135 M | 2.127 M | 2.171 M | 2.257 M | 2.320 M | 2.333 M | 2.400 M | 2.218 M | |
Long term debt | 4.495 M | 3.767 M | 3.257 M | 2.780 M | 2.226 M | 1.591 M | 1.010 M | 561.000 K | |
Other liabilities | 38.592 M | 37.744 M | 2.682 M | 1.347 M | 695.000 K | 2.476 M | 1.730 M | 0.000 | |
Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Total Shareholder equity | 225.517 M | 305.776 M | 279.517 M | 251.244 M | 245.414 M | 233.368 M | 212.082 M | 231.953 M | |
Common stock | 41.900 M | 41.946 M | 41.981 M | 42.041 M | 42.090 M | 42.103 M | 42.140 M | 42.234 M | |
Retained earnings | -283.116 M | -207.655 M | -239.313 M | -274.254 M | -286.200 M | -305.079 M | -333.109 M | -319.947 M |